ORIGINAL ARTICLE

Volumetric regression ratio of the primary tumor and metastatic lymph nodes after induction chemotherapy predicts overall survival in head and neck squamous cell carcinoma: a retrospective analysis

Olgun Elicin[1], Michael Schmücking[1], Jens Brömme[1], Daniel Rauch[2], Pinar Ambarcioglu[3], Ludwig Plasswilm[4], Andreas Geretschläger[1], Pirus Ghadjar[5], Roland Giger[6*], Daniel M. Aebersold[1*]

[1]Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland; [2]Department of Medical Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland; [3]Department of Biostatistics, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey; [4]Department of Radiation Oncology, Kantonspital St. Gallen, St. Gallen, Switzerland; [5]Department of Radiation Oncology, Charité Universitätsmedizin Berlin, Berlin, Germany; [6]Department of Otorhinolaryngology - Head and Neck Surgery, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland

*These authors contributed equally to this work

Summary

Purpose: We looked for any predictive value of change in primary tumor and metastatic lymph node volumes after induction chemotherapy (IC) on oncologic outcome in head and neck squamous cell carcinoma (HNSCC).

Methods: Nineteen patients with stage IVA/B HNSCC treated between 2004 and 2010 with at least one cycle of IC (docetaxel, cisplatin and 5-fluorouracil / TPF) and concomitant chemoradiotherapy (CRT) with cisplatin were retrospectively analyzed. Volumes were calculated separately for primary tumor (Vtm), lymph node metastases (Vln) and their sum (Vsum) on computed tomography (CT) images before and after IC. The effect of volumetric changes on locoregional failure (LRF), distant metastasis (DM) and overall survival (OS) was assessed. P values <0.05 were considered as statistically significant.

Results: The median follow-up of surviving patients was 25 months (range: 10.7-83.3). The median number of cycles and duration of TPF was 3 (range: 1-4) and 44 days

(range: 4-116), respectively. Empirical area under the curve (AUC) analyses for death, LRF and DM revealed optimal cut-off values of Vtm diminution (30.54%, AUC: 87%) and Vsum decrease (35.45%, AUC: 64.55%) only for OS (p <0.05). Among those, a reduction in Vsum more than 35.4% between pre- and post-IC was significantly correlated with better OS (100 vs 43% at 2 years, p <0.05).

Conclusion: Volumetric shrinkage of the tumor load after IC assessed with CT seems to predict OS. The assessment of volumetric shrinkage upon IC might be used to decide whether to offer patients alternative strategies like palliative/de-intensified treatments or more aggressive combined modalities after IC.

Key words: computed tomography, head and neck squamous cell carcinoma, induction chemotherapy, survival, volume

Introduction

Concomitant CRT is the standard therapeutic strategy for unresectable locoregionally advanced HNSCC [1]. When IC is administered, TPF chemo- therapy has been shown to be superior to cisplatin and 5-fluorouracil only [2-4]. However, the debate whether to add IC prior to CRT is still ongoing.

The updated MACH-NC meta-analysis [1] and the recently presented meta-analysis by Budach et al. [5] did not show any superiority of IC followed by CRT over CRT alone. Recently published randomized trials did not present consistent results favoring IC [6-9]. The only new positive trial by Ghi et al. [9] had a 2x2 factorial design and concomitant treatment arms contained either cisplatin or cetuximab as systemic agent (full text not published), which makes it difficult to draw a sound conclusion. The multidisciplinary Head and Neck Tumor Board of the University Hospital of Bern selected only patients indicated for TPF IC before CRT in case of locoregionally advanced disease with inoperable tumor and/or nodal masses which would also require extremely large target volumes and frequent adaptive re-planning in case of definitive CRT.

In HNSCC, the routinely used basic standard to estimate the outcome is the TNM stage. It takes the largest diameter and the anatomical local extent of disease, the number and size of involved lymph nodes and the presence or absence of distant metastases into account. On the other hand, it is also shown that the volumetric staging can be superior to TNM staging regarding prediction of outcome and TNM staging is not always correlated with the extent of disease burden [10-12].

Several studies were published demonstrating the predictive value of pre-treatment volume of primary tumor and/or involved lymph nodes on outcome in locoregionally advanced HNSCC treated with either surgery, CRT or radiation alone [13,14]. In addition, the ratio of volumetric change during CRT might also be predictive for local failure [15]. However, there is no consensus about any standard volumetric cut-off value to be used for volumetric staging.

In the past 10 years, some centers have begun to use IC routinely either as a standard protocol for locoregionally advanced HNSCC or just for selected cases having very advanced disease. Bisdas et al. [16] have associated tumor volume with CT prior to IC on 19 patients to disease-free survival (DFS).

The goal of this study was to look for any predictive value of volumetric change in primary tumor and metastatic lymph nodes due to IC on LRF, DM and OS in patients with locoregionally advanced HNSCC definitively treated with CRT after induction therapy. To our knowledge no article has yet been published regarding any predictive value of volumetric changes after IC on oncological outcome.

Methods

Between 2004 and 2010, 389 cases diagnosed with oral, oropharyngeal, laryngeal and hypopharyngeal primary cancer were treated with definitive CRT. In this cohort, 40 patients with stage IVA/B (UICC/AJCC 7th edition) biopsy-proven HNSCC treated with at least one cycle of IC and definitive CRT were retrospectively analyzed. The study was approved by the local Ethics Committee in accordance with the Helsinki Declaration. Clinical staging was based on ENT-examination, panendoscopy and head and neck CT with or without ^{18}F-Fluorodeoxyglucose positron emission tomography (^{18}FDG-PET)-CT (thoracic CT in case of no ^{18}FDG PET-CT). Twenty-one patients were excluded: 19 had missing digitalized imaging or data, 1 had a previously treated disease with lymph node recurrence, and another one received 5 cycles of IC due to patient related reasons.

IC consisted of docetaxel 75 mg/m² as infusion over one hour followed by cisplatin 75 mg/m² as infusion over one hour on day 1, followed by fluorouracil 1000 mg/m² as continuous infusion for 4 days. Concomitant chemotherapy consisted of 2-3 cycles of cisplatin 100 mg/m² 3-weekly. Cetuximab or carboplatin were used alternatively in patients in whom cisplatin was contraindicated. All patients were irradiated using intensity-modulated radiotherapy (IMRT) technique up to 72 Gy with 2 Gy per fraction, 5 times per week as we have described in detail in a previous article [17].

To compare the volumetric change in tumor burden after IC, Vtm, Vln and Vsum before and after the completed course of IC were calculated as follows: initial pre-IC images were imported into our radiotherapy treatment planning system (Eclipse version 11.0, Varian, Palo Alto CA, USA). CT images performed before CRT for treatment planning were already stored in our system. The primary tumor and metastatic lymph nodes were contoured by the same radiation oncologist separately in each image set (Figure 1). Metastatic lymph nodes were defined as nodes with a diameter of ≥10 mm in short axis (except for the jugulodigastric and retropharyngeal nodes in which ≥15 mm and ≥8 mm were considered as malignant, respectively). At the end, all volumes were revised by a radiologist to avoid possible errors and improve accuracy. Volumes in cm³ (mL) were calculated with the volume calculation algorithm of the treatment planning software and recorded separately for Vtm, Vln and Vsum on the pre-IC and post-IC image sets for comparison.

Statistics

Descriptive statistics for patient characteristics were calculated. All time-to-event endpoints were calculated from the start of IC. Difference of volumes pre- to post-IC was assessed with paired Sign test. Ratios of volumetric change after IC were calculated for Vtm, Vln and Vsum respectively. Receiver operating

Figure 1. Primary tumor (red) and metastatic lymph node (blue) structures pre-(**A**) and post-IC (**B**) based on CT delination.

Figure 2. Change in volumes of primary tumor, involved lymph nodes and their sum.
IC: Induction chemotherapy, Vtm: Volume of the primary tumor, Vln: Volume of metastatic lymph nodes, Vsum: Vtm + Vln

characteristic (ROC) analyses were done for endpoints of LRF, DM and OS with an optimized sensitivity and specificity defined cut-off with the largest AUC. Survival curves for LRF, DM and OS were constructed with the Kaplan-Meier method and predictive value of cut-off ratios regarding survival, LRF and DM were tested with log-rank test. P values <0.05 were considered as statistically significant. SPSS software version 15 (IBM, Chicago IL, USA) and JMP 9.0 (SAS Institute Inc. North Carolina, US) were used for statistical analyses.

Results

The median patient age was 60 years (range: 41-73). Ten patients had their primary tumors

arising from the oropharynx, 6 from larynx and 3 from hypopharynx. The median number of cycles and duration of TPF was 3 (range: 1-4) and 44 days (range: 4-116), respectively. Five patients were administered 1-2 cycles of TPF, 11 received 3 cycles and 3 received 4 cycles based on multidisciplinary tumor board decision. Six patients had interruptions of CRT related to acute toxicity for a median of 2 days (range: 1-5). The median follow-up of surviving patients was 25 months (range: 10.7 – 83.3). Statistically, none of those parameters were associated with survival.

Initial and post-IC mean volumes and related mean changes in percent are given in Table 1 and Figure 2. One patient did not have any lymph node metastases but only an extensive primary tumor.

Empirical AUC analyses for death, LRF and DM revealed significant optimal cut-off values of Vtm reduction (-30.54%, AUC: 87%) and Vsum reduction (-35.45%, AUC: 64.55%) only for OS ($p <0.05$). To predict the OS, the 35.45% decrease of Vsum was statistically significant in log-rank test (Figure 3). If the total radiological visible volume containing tumor and involved lymph node mass shrunk at least 35.45% after IC, OS at 2 years was significantly higher (100 vs 43%, $p <0.05$).

Discussion

Several studies and review articles have been published about the significant predictive value of primary tumor volume, metastatic lymph node volume and their sum on varying endpoints of outcome (local control, LRC, DM, OS and DFS) [13,14]. However, there is no consensus about the volume thresholds to be used. Only Studer et al. [12,18-20] extensively studied this issue and consistently used a classification system divided by three thresholds.

Before the development and widespread use of software which enables 3D measurement of the volumes on images, cuboid and ellipsoid volume formulas ($a×b×c$ and $1/6 \; x\pi×a×b×c$, respectively)

Figure 3. Overall survival stratified according Vsum reduction after IC. IC: Induction chemotherapy, Vsum: Sum of the primary tumor and metastatic lypmh node(s).

were used to estimate the tumor and metastatic lymph node volumes [21-23]. Thanks to advances in imaging technologies some authors also included CT-based radiological indicators like lymphatic extracapsular spread [24], central nodal necrosis [21,25] or perfusion parameters [26] for predicting outcome and found significant results related to those factors. But in our study we did not include criteria other than simple volumetric parameters in standard contrast enhanced CT.

Almost all studies published on this subject evaluated the tumor burden before CRT or radiotherapy alone. Few articles about the value of tumor volume before IC were mostly focused on the correlation of volume with chemotherapy effects like tumor remission [27] or negative biopsy results [28]. Bisdas et al. [16] measured primary tumor volume with CT before IC and found a significant correlation with decreased DFS. Seol et al. [29] and Yu et al. [30] used metabolic primary tumor volume prior to IC measured with ^{18}FDG-PET-CT and found significant correlation

Table 1. Measured volumes of primary tumor, metastatic lymph nodes and their sum

Measured volume	Mean pre-IC volume in mL (range)	Mean post-IC volume in mL (range)	Mean relative change (%)
Vtm	45.3 (2.4-103.1)	25.4 (0-95.8)	-43.6
Vln	58.1 (0-334.7)	22.7 (2.26-116.6)	-39.0
Vsum	103.3 (13.81-392)	48.2 (4.8-148.1)	-39.7

IC: Induction chemotherapy, Vtm: Volume of the primary tumor, Vln: Volume of metastatic lymph nodes, Vsum: Vtm + Vln

with DFS. The methodologically most similar attempt to our current study was from Yoon et al. [31] where they demonstrated the correlation of the percentage of maximum standardized uptake value (SUVmax) decrease regarding primary tumor or metastatic lymph nodes after IC with the outcomes including clinical complete response, LRF and OS in a cohort of 21 patients. It was a study showing a relation between outcome and a quantitative ratio measurable from the start of IC to its end before CRT. However, the IC regimen was a non-standard protocol used in East Asia and the volumetric assessment was done with metabolic response and not with morphological changes.

Detailed results and treatment related toxicities of this cohort is published previously [17]. To our knowledge, the present study is the first to evaluate the volumes before and after IC using proportional change in morphology, taking both primary tumor and metastatic lymph nodes into consideration. We evaluated the predictive value of total locoregional tumor shrinkage of at least -35% after IC on OS. It is also interesting to see, that our cut-off value is close to the partial response threshold of -30%, defined by the widely accepted RECIST guideline [32] where the use of one-dimensional longest diameter but not a 3D volumetric assessment is required. On the other hand, it is interesting to observe a significant effect of volume change on OS without being able to find any optimal cut-off value for LRF or DM. The underlying reason for this lack of significance might be the limited sample size or another parameter we are not aware of.

The major limitation of our study besides its retrospective nature is the heterogeneity and the limited number of the patient cohort. In addition, the number of IC cycles varied due to toxicity. Moreover, patients responding to one or two cycles could typically continue to respond during the next cycles. The cut-off value what we defined should be 'fine-tuned' with future studies having larger sample sizes. HNSCC, even with the same histopathology, follows different clinical courses regarding the primary tumor site. This is why it will be impossible to generate a uniform algorithm for all subsites of the head and neck area. Therefore it is important to have cases with homogeneous disease sites or stratified large cohorts in studies like this.

Today, administering TPF IC for locoregionally advanced HNSCC is justified and widely accepted, based on a high level of evidence only for larynx preservation purposes [33,34]. On the other hand, to choose IC for cases having extensive bulky disease remains to be an option.

By using these simple volumetric measurements to calculate the volume reduction of the tumor mass after IC, it may be possible to assess patients who may be offered modalities combined with radical and morbid surgical options and closer follow-up, or on the contrary, offer those poor responders less aggressive palliative approaches with modified radiation dose/fractionation/volume concepts (e.g. less total dose, split course, no elective irradiation), no or less toxic CRT. The CT-based method to calculate the volumes may be implemented in countries and healthcare settings where resources for other imaging techniques like ^{18}FDG-PET-CT are limited.

Conclusion

Primary tumor together with metastatic lymph node volume reduction after IC with a cut-off value of at least -35.45% seems to be predictive on OS in patients with stage IVA/B HNSCC. Shrinkage of the total locoregional tumor volume less than this cut-off value has an OS of 43% in comparison to a higher volume reduction with an OS of 100% at 2 years. However, these results need to be validated in future prospective studies with larger sample sizes to allow establishing their value as a measurement tool of stratification and allocation to treatment strategies.

References

1. Pignon J-P, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14.

2. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715.

3. Vermorken JB, Remenar E, van Herpen C et al. Cispla-

tin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-1704.

4. Blanchard P, Bourhis J, Lacas B et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 2013;31:2854-2860.

5. Budach W, Boelke E, Kammers K, Gripp S, Matuschek C. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy as treatment of unresected locally advanced head and neck cancer squamous cell cancer (HNSCC): A meta-analysis of randomized trials. J Clin Oncol 2014;32(5s):Suppl; abstr 6012.

6. Haddad R, O'Neill A, Rabinowits G et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013;14:257-264.

7. Cohen EEW, Karrison TG, Kocherginsky M et al. Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer. J Clin Oncol 2014;32:1-13.

8. Hitt R, Grau JJ, López-Pousa A et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 2014;25:216-225.

9. Ghi MG, Paccagnella A, Ferrari D et al. Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III fac. J Clin Oncol 2014;32(5s):Suppl; abstr 6004.

10. Piccirillo JF. Purposes, problems, and proposals for progress in cancer staging. Arch Otolaryngol Head Neck Surg 1995;121:145-149.

11. Johnson CR, Khandelwal SR, Schmidt-Ullrich RK, Ravalese J, Wazer DE. The influence of quantitative tumor volume measurements on local control in advanced head and neck cancer using concomitant boost accelerated superfractionated irradiation. Int J Radiat Oncol Biol Phys 1995;32:635-641.

12. Studer G, Lütolf UM, El-Bassiouni M, Rousson V, Glanzmann C. Volumetric staging (VS) is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT. Acta Oncol 2007;46:386-894.

13. Lodder WL, Pameijer FA, Rasch CRN, van den Brekel MWM, Balma JM. Prognostic significance of radiologically determined neck node volume in head and neck cancer: a systematic review. Oral Oncol 2012;48:298-302.

14. Rutkowski T. The role of tumor volume in radiotherapy of patients with head and neck cancer. Radiat Oncol 2014;9:23.

15. Bhatia KSS, King AD, Yu K-H et al. Does primary tumour volumetry performed early in the course of definitive concomitant chemoradiotherapy for head and neck squamous cell carcinoma improve prediction of primary site outcome? Br J Radiol 2010;83:964-970.

16. Bisdas S, Rumboldt Z, Wagenblast J et al. Response and progression-free survival in oropharynx squamous cell carcinoma assessed by pretreatment perfusion CT: comparison with tumor volume measurements. AJNR Am J Neuroradiol 2009;30:793-799.

17. Brömme JO, Schmücking M, Arnold A et al. Taxane-containing induction chemotherapy followed by definitive chemoradiotherapy. Outcome in patients with locally advanced head and neck cancer. Strahlenther Onkol 2013;189:618-624.

18. Studer G, Rordorf T, Glanzmann C. Impact of tumor volume and systemic therapy on outcome in patients undergoing IMRT for large volume head neck cancer. Radiat Oncol 2011;6:120.

19. Studer G, Glanzmann C. Volumetric staging in oropharyngeal cancer patients treated with definitive IMRT. Oral Oncol 2013;49:269-276.

20. Studer G, Glanzmann C. Volumetric stratification of cT4 stage head and neck cancer. Strahlenther Onkol 2013;189:867-873.

21. Grabenbauer GG, Steininger H, Meyer M et al. Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. Radiother Oncol 1998;47:175-183.

22. Jakobsen J, Hansen O, Jørgensen KE, Bastholt L. Lymph node metastases from laryngeal and pharyngeal carcinomas - Calculation of burden of metastasis and its impact on prognosis. Acta Oncol 1998;37:489-493.

23. Chufal KS, Rastogi M, Srivastava M, Pant MC, Bhatt MLB, Srivastava K. Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume. Jpn J Clin Oncol 2006;36:537-546.

24. Vergeer MR, Doornaert P, Leemans CR, Buter J, Slotman BJ, Langendijk J. Control of nodal metastases in squamous cell head and neck cancer treated by radiation therapy or chemoradiation. Radiother Oncol 2006;79:39-44.

25. Munck JN, Cvitkovic E, Piekarski JD et al. Computed tomographic density of metastatic lymph nodes as a treatment-related prognostic factor in advanced head and neck cancer. J Natl Cancer Inst 1991;83:569-575.

26. Bisdas S, Nguyen SA, Anand SK, Glavina G, Day T, Rumboldt Z. Outcome prediction after surgery and chemoradiation of squamous cell carcinoma in the oral cavity, oropharynx, and hypopharynx: use of baseline perfusion CT microcirculatory parameters vs. tumor volume. Int J Radiat Oncol Biol Phys 2009;73:1313-1318.

27. Baghi M, Mack MG, Hambek M et al. Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy. Head Neck 2007;29:104-108.

28. Chepeha DB, Sacco AG, Oxford LE et al. Advanced squamous cell carcinoma of the oropharynx: efficacy of positron emission tomography and comput-

ed tomography for determining primary tumor response during induction chemotherapy. Head Neck 2009;31:452-460.

29. Seol YM, Kwon BR, Song MK et al. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol 2010;49:201-208.

30. Yu J, Cooley T, Truong M-T, Mercier G, Subramaniam RM. Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: Value of FDG volumetric imaging parameters. J Med Imaging Radiat Oncol 2014;58:18-24.

31. Yoon DH, Cho Y, Kim SY et al. Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemo-

therapy followed by concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2011;81:118-125.

32. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.

33. Lefebvre JL, Pointreau Y, Rolland F et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 2013;31:853-859.

34. Pointreau Y, Garaud P, Chapet S et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009;101:498-506.